

# Bravecto (fluralaner) chewable tablets have been thoroughly evaluated in multiple countries and are approved as a safe and effective flea, tick and mite treatment for dogs

Walter Comas<sup>1</sup>, Rob Armstrong<sup>2</sup>

<sup>1</sup>MSD Animal Health, Buenos Aires, Argentina

<sup>2</sup>MSD Animal Health, 2 Giralda Farms, Madison, NJ USA

**Abstract** — *Bravecto (fluralaner) is thoroughly tested to international safety standards for veterinary drugs, meeting approval requirements for over 70 countries. This valuable antiparasite (fleas, ticks and mites) treatment contributes to the health of millions of dogs and promotes dog health worldwide by protecting them against dangerous parasite infestations that are known to lead to pathogen transmission, blood loss, local irritation, and skin allergies. In 2017, the European Medicines Agency (EMA) completed an in depth targeted review of all reported adverse events (ADE) related to various potential disorders and confirmed the positive benefit-risk profile of Bravecto. Official records that monitor adverse events are often available online and these reports can be easily misunderstood by people unfamiliar with the procedures and how to interpret monitoring information. For example, many people do not know that the FDA advises “For any given ADE report, there is no certainty that the reported drug caused the adverse event.” This means that the cause of a problem reported to this agency has not been determined, and this is typical of drug use reports. Multiple communications from individual dog and cat owners provided photographs showing how their pet has dramatically improved with the help of fluralaner treatment.*

**Keywords**— *cat, dog, fluralaner, pharmacovigilance, safety.*

## I. INTRODUCTION

Fluralaner is the active ingredient in the Bravecto Chew (MSD Animal Health, Giralda Farms, NJ, USA), a treatment that offers a highly effective way to control external arthropod parasites affecting dogs, including fleas, ticks and mites, for up to 12 weeks following a single dose. This treatment is approved in over 70 countries based on careful review of a comprehensive dossier consisting of multiple field and laboratory studies proving the safety and efficacy of fluralaner. In addition, there are more than fifty peer-reviewed publications available in the scientific literature that provide expert scientific evidence of the safety and efficacy of fluralaner [1-50].

All approved medicines go through an intensive ongoing safety monitoring service to evaluate any potential problems that may become apparent with experience but that did not show up even under intensive pre-approval testing. This monitoring evaluation is called pharmacovigilance and the process follows strict rules that allow experts in the area to detect evidence of any kind of “safety signal”. This signal may indicate a previously unrecognized problem with a medicine and be a sign that users should be informed of additional information regarding the profile of the product.

Many regulatory authorities provide access to the public to the reported pharmacovigilance data on approved veterinary products, such as fluralaner. Unfortunately, this information is potentially misinterpreted by some readers, who are uninformed as to how these reports are prepared and assume that every report is an indication that the medicine caused the problem. The careful reader, on the other hand, quickly realizes that this is not the case. In addition to pharmacovigilance, medicines may also be evaluated in other safety studies performed after launch. For example, studies may be conducted because the active ingredient in a veterinary medicine is being reviewed for other uses in other animal species.

Fluralaner belongs to a class of flea and tick treatment drugs called the isoxazolines that distribute systemically in the dog after administration, so that the medicine spreads through the bloodstream to all areas of the skin. These medicines kill the flea or tick when it tries to bite and is then exposed to the active ingredient. Multiple studies on both fleas and ticks have now shown that this approach to controlling these parasites can prevent the damaging effects associated with these bites, including prevention of allergies to biting parasite saliva and reducing the risk of parasite borne disease transmission. The isoxazolines were superior to a topically administered treatment for killing ticks attached to dogs at the time of treatment [28].

## II. MATERIALS AND METHODS

All peer reviewed scientific literature and on-line published scientific sources regarding the safety and efficacy of fluralaner were identified and reviewed [1-56]. There are over fifty relevant publications providing in depth review of the mechanism of action, the safety of treating dogs and cats and effectiveness against multiple parasitic infestations. These papers are indexed in multiple scientific databases and are often freely available online to all readers. In addition there are online reports available from government agencies that document the safety of fluralaner, including some unique studies not available for any other isoxazoline approved for treatment of dogs that were reviewed in preparation of this report [57].

## III. RESULTS AND DISCUSSION

A unique and comprehensive body of scientific work supports the use of fluralaner against external parasites affecting dogs and cats. Careful and knowledgeable review of the scientific literature confirms the well-documented safety and efficacy profile of fluralaner for dog and cat treatment. Government agency intensive reviews of all adverse event reports from everywhere around the world find that the risk-benefit profile for use of this treatment is positive.

Recent investigations into the safety of fluralaner use in dogs present new evidence for the safety profile of fluralaner following administration [57]. Fluralaner was administered to dogs daily at up to 4 mg/kg for one year (52 weeks) without report of a serious adverse event. The same reference also reports no adverse events in dogs receiving very high fluralaner doses (up to 750 mg/kg) daily for 28 consecutive days [57].

Additional evidence and testimonials from pet owners, while anecdotal, further confirm the often dramatic effect that fluralaner treatment can produce in parasite-infested dogs (Figures 1-7). The illustrations below were provided by pet owners who documented the dramatic improvement seen in their formerly parasite-affected animals following fluralaner treatment. In at least one case, the owner was so desperate for an effective treatment and concerned about the discomfort their dog was in that they were considering euthanasia.



**FIGURE 1. Head on and lateral view of a dog with a severe skin parasitic infestation just before treatment with Bravecto (fluralaner).**



**FIGURE 2. The same dog as in fig. 1 photographed 8 weeks later. (Photo credit Emma O'Brien, used with permission)**



**FIGURE 3. Another untreated dog with a severe skin parasitic disease**



**FIGURE 4. The same dog as in fig. 3 photographed 8 weeks after fluralaner treatment**



**FIGURE 5. A puppy presented with severe parasitic skin disease (on the left) and the same puppy 8 weeks later following treatment with fluralaner (on the right).**



**FIGURE 6. Heavy tick infestation in the ear of a dog before treatment with fluralaner.**



**FIGURE 7. The same dog as in Fig. 6 one week following fluralaner treatment**

One frequent source of information regarding potential adverse events associated with treatments is the US FDA adverse drug event database. The US FDA provides clear statements for this database to help readers correctly interpret the report numbers, but these guidelines may be ignored or misunderstood by individuals who review information from the database and then present these numbers in their published work. It is helpful to review the recommendations the US FDA makes to help readers understand these reports and to consider their meaning:

- “For any given ADE report, there is no certainty that the reported drug caused the adverse event. The adverse event may have been related to an underlying disease, using other drugs at the same time, or other non-drug related causes. The clinical detail listing does not include information about underlying diseases, other drugs used at the same time, other non-drug related causes, or the final outcome of the reaction.
- The accuracy of information regarding the ADE is dependent on the quality of information received from the reporting veterinarian or animal owner.
- Accumulated ADE reports should not be used to calculate incidence rates or estimates of drug risk, because there is no accurate way to determine how many animals were given the drug, which is needed as the denominator in calculations of incidence and relative risk.
- It is inappropriate to make use of adverse event data to compare the safety of different products. For example, if a drug is widely used to treat certain conditions, there may be more ADEs for that drug than another product that is not used as often. This would not mean that the first drug was more unsafe than the second.

- The number of reports simply represents the number of ADEs received for a particular drug and should not be used for any type of comparison purposes.
- Underreporting occurs with most adverse event reporting systems. The frequency of reporting for a given drug product varies over time, and may be greater when the drug is newly marketed, or when media publicity occurs.
- Information on how the drugs were used (for indications on the product label or in an extra label manner) is not provided in the clinical detail listing.”

These cautionary statements make it clear that the ADE database information needs to be interpreted by people who understand how summarized reports can be used to look for evidence of safety signals. These reports should not be presented as evidence of lack of drug safety and this would be an incorrect conclusion without more background details. Those who have the expertise to assess such reports – namely the global regulatory agencies – have concluded that the benefit-risk profile of Bravecto remains favorable.

#### IV. CONCLUSION

The scientific literature contains convincing data showing that Bravecto (fluralaner) offers a unique combination of long lasting efficacy and safety for dogs and cats and provides multiple benefits for pet owners of pets by helping them to prevent dangerous parasite skin infestations with fleas, ticks and mites.

#### ACKNOWLEDGEMENTS

The authors gratefully acknowledge New Beginnings Rescue Centre, Community Led Animal Welfare and Emma O'Brien for photographs and the permission to use these. Thank you also to the many thousands of veterinarians and millions of pet parents who strive every day to improve the health of their dogs and cats based on careful science and thoughtful understanding and who are not swayed by unsupported internet rumors.

#### REFERENCES

- [1] N. Rohdich, R.K.A. Roepke, and E. Zschiesche. “A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto (fluralaner) against Frontline™ (fipronil) in flea- and tick-infested dogs.” *Parasites & Vectors* 2014 7:83
- [2] F.M. Walther, M.J. Allan, R.K.A. Roepke, and M.C. Nuernberger. “The effect of food on the pharmacokinetics of oral fluralaner in dogs” *Parasites & Vectors* 2014 7:84
- [3] F.M. Walther, A.J. Paul, M.J. Allan, R.K.A. Roepke, and M.C. Nuernberger. “Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration” *Parasites & Vectors* 2014 7:86
- [4] S. Kilp, D. Ramirez, M.J. Allan, R.K.A. Roepke, M.C. Nuernberger. “Pharmacokinetics of fluralaner in dogs following a single oral or intravenous administration” *Parasites & Vectors* 2014 7:85
- [5] F.M. Walther, M.J. Allan, R.K.A. Roepke, and M.C. Nuernberger. “Safety of fluralaner chewable tablets (Bravecto), a novel systemic antiparasitic drug, in dogs after oral administration.” *Parasites & Vectors* 2014 7:87
- [6] F.M. Walther, P. Fisara, M.J. Allan, R.K.A. Roepke, and M.C. Nuernberger. “Safety of the concurrent treatment of dogs with Bravecto™ (fluralaner) and Scalibor™ protectorband (deltamethrin)” *Parasites & Vectors* 2014 7:105
- [7] H. Williams, D.R. Young, T. Qureshi, H. Zoller, and A.R. Heckerroth. “Fluralaner, a novel isoxazoline, prevents flea (*Ctenocephalides felis*) reproduction in vitro and in a simulated home environment.” *Parasites & Vectors* 2014 7:275
- [8] C. Meadows, F. Guerino, F. Sun. “A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling canine flea infestations.” *Parasites & Vectors* 2014 7:375
- [9] F.M. Walther, P. Fisara, M.J. Allan, R.K.A. Roepke, and M.C. Nuernberger. “Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime – praziquantel” *Parasites & Vectors* 2014 7:481
- [10] C. Wengenmayer, H. Williams, E. Zschiesche, A. Moritz, J. Langenstein, R.K.A. Roepke, and A.R. Heckerroth. “The speed of kill of fluralaner (Bravecto™) against *Ixodes ricinus* ticks on dogs.” *Parasites & Vectors* 2014 7:525
- [11] J.Taenzler, C. Wengenmayer, H. Williams, J. Fourie, E. Zschiesche, R.K.A. Roepke, and A.R. Heckerroth. “Onset of activity of fluralaner (BRAVECTO™) against *Ctenocephalides felis* on dogs.” *Parasites & Vectors* 2014 7:567
- [12] H. Williams, H. Zoller, R.K.A. Roepke, E. Zschiesche, and A.R. Heckerroth. “Fluralaner activity against life stages of ticks using *Rhipicephalus sanguineus* and *Ornithodoros moubata* IN *in vitro* contact and feeding assays.” *Parasites & Vectors* 2015 8:90
- [13] J.J. Fourie, J.E. Liebenberg, I.G. Horak, J. Taenzler, A.R. Heckerroth, and R. Frénais. “Efficacy of orally administered fluralaner (Bravecto™) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs.” *Parasites & Vectors* 2015 8:187
- [14] P. Fisara and M. Webster. “A randomized controlled trial of the efficacy of orally administered fluralaner (Bravecto™) against induced *Ixodes holocyclus* (Australian paralysis tick) infestations on dogs.” *Parasites & Vectors* 2015 8:257

- [15] J. Taenzler, J. Liebenberg, R.K.A. Roepke, and A.R. Heckerroth. "Prevention of transmission of *Babesia canis* by *Dermacentor reticulatus* ticks to dogs treated orally with fluralaner chewable tablets (Bravecto™)." *Parasites & Vectors* 2015 8:305
- [16] H. Williams, J. Demeler, J. Taenzler, R.K.A. Roepke, E. Zschiesche, and A.R. Heckerroth. "A quantitative evaluation of the extent of fluralaner uptake by ticks (*Ixodes ricinus*, *Ixodes scapularis*) in fluralaner (Bravecto) treated vs. untreated dogs using the parameters tick weight and coxal index." *Parasites & Vectors* 2015 8:352
- [17] M.W. Dryden, V. Smith, T. Bennett, L. Math, J. Kallman, K. Heaney, and F. Sun. "Efficacy of fluralaner flavored chews (Bravecto®) administered to dogs against the adult cat flea, *Ctenocephalides felis felis* and egg production." *Parasites & Vectors* 2015 8:364
- [18] F.M. Walther, M.J. Allan, and R.K.A. Roepke. "Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs." *Parasites & Vectors* 2015 8:508
- [19] O. Crosaz, E. Chapelle, N. Cochet-Faivre, D. Ka, C. Hubinois, J. Guillot. "Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region ." *Parasites & Vectors* 2016 9:174
- [20] J. Taenzler, B. Gale, E. Zschiesche, R.K.A. Roepke, and A.R. Heckerroth. "The effect of water and shampooing on the efficacy of fluralaner spot-on solution against *Ixodes ricinus* and *Ctenocephalides felis* infestations in dogs." *Parasites & Vectors* 2016 9:233
- [21] S. Kilp, D. Ramirez, M.J. Allan, and R.K.A. Roepke. "Comparative pharmacokinetics of fluralaner in dogs and cats following single topical or intravenous administration." *Parasites & Vectors* 2016 9:296
- [22] J. Taenzler, J. Liebenberg, M. Mienie, W.R. Everett, D.R. Young, T.S. Vihelic, F. Sun, E. Zschiesche, R.K.A. Roepke, and A.R. Heckerroth. "Efficacy of fluralaner spot-on solution against induced infestations with *Rhipicephalus sanguineus* on dogs." *Parasites & Vectors* 2016 9:276
- [23] J. Taenzler, J. Liebenberg, R.K.A. Roepke, and A.R. Heckerroth. "Prevention of transmission of *Babesia canis* by *Dermacentor reticulatus* ticks to dogs after topical administration of fluralaner spot-on solution." *Parasites & Vectors* 2016 9:234
- [24] F.M. Walther, M.J. Allan, and R.K.A. Roepke. "Safety of concurrent treatment of cats with fluralaner and emodepside-praziquantel." *Parasites & Vectors* 2016 9:322
- [25] M.W. Dryden, M.S. Canfield, K. Kalosy, A. Smith, L. Crevoiserat, J.C. McGrady, K.M. Foley, K. Green, C. Tebaldi, V. Smith, T. Bennett, K. Heaney, L. Math, C. Royal, and F. Sun. "Evaluation of fluralaner and afoxolaner treatments to control flea populations, reduce pruritus and minimize dermatologic lesions in naturally infested dogs in private residences in west central Florida USA." *Parasites & Vectors* 2016 9:365
- [26] J. Taenzler, J. Liebenberg, R.K.A. Roepke, R. Frénais, and A.R. Heckerroth. "Efficacy of fluralaner administered either orally or topically for the treatment of naturally acquired *Sarcoptes scabiei* var. *canis* infestation in dogs." *Parasites & Vectors* 2016 9:392
- [27] K. Pfister and R. Armstrong. "Systemically and cutaneously distributed ectoparasiticides: a review of the efficacy against ticks and fleas on dogs." *Parasites & Vectors* 2016 9:436
- [28] F. Burgio, L. Meyer, and R. Armstrong. "A comparative laboratory trial evaluating the immediate efficacy of fluralaner, afoxolaner, sarolaner and imidacloprid + permethrin against adult *Rhipicephalus sanguineus* (sensu lato) ticks attached to dogs." *Parasites & Vectors* 2016 9:626
- [29] J. Taenzler, C. de Vos, R.K.A. Roepke, R. Frénais, and A.R. Heckerroth. "Efficacy of fluralaner against *Otodectes cynotis* infestations in dogs and cats." *Parasites & Vectors* 2017 10:30
- [30] C. Meadows, F. Guerino, and F. Sun. "A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling canine flea infestations." *Parasites & Vectors* 2017 10:36
- [31] C. Meadows, F. Guerino, and F. Sun. "A randomized, blinded, controlled USA field study to assess the use of fluralaner topical solution in controlling feline flea infestations." *Parasites & Vectors* 2017 10:37
- [32] R.P. Lavan, K. Tunceli, D. Zhang, D. Normile, and R. Armstrong. "Assessment of dog owner adherence to veterinarians' flea and tick prevention recommendations in the United States using a cross-sectional survey." *Parasites & Vectors* 2017 10:284
- [33] H. Kohler-Aanesen, S. Saari, R. Armstrong, K. Péré, J. Taenzler, E. Zschiesche, and A.R. Heckerroth. "Efficacy of fluralaner (Bravecto™ chewable tablets) for the treatment of naturally acquired *Linognathus setosus* infestations on dogs." *Parasites & Vectors* 2017 10:426
- [34] H. Dongus, L. Meyer, and R. Armstrong. "Water immersion of dogs close to the time of topical fluralaner treatment does not reduce efficacy against a subsequent experimental challenge with *Rhipicephalus sanguineus* (sensu lato)." *Parasites & Vectors* 2017 10:441
- [35] M. Asahi, M. Kobayashi, H. Matsui, and K. Nakahira. "Differential mechanisms of action of the novel  $\gamma$ -aminobutyric acid receptor antagonist ectoparasiticides fluralaner (A1443) and fipronil." *Pest Manag Sci* 2014
- [36] M. Gassel, C. Wolf, S. Noack, H. Williams, and T. Ilg. "The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod  $\gamma$ -aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity." *Insect Biochemistry and Molecular Biology* 45 (2014) 111-124
- [37] K. Allen, S. Little, F. Guerino, M. Petersen and M. Wray. "Efficacy of fluralaner against nymphal stages of *Rhipicephalus sanguineus* and *Amblyomma americanum*." AAVP Congress 2015 Abstract
- [38] Y. Ozoe, M. Asahi, F. Ozoe, K. Nakahira, and T. Mita. "The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels." *Biochemical and Biophysical Research Communications* 2010 391:744-749
- [39] Y. Ozoe. " $\gamma$ -Aminobutyrate- and Glutamate-gated Chloride Channels as Targets of Insecticides." *Advances in Insect Physiology*, Volume 44 Chapter 4
- [40] R.P. Lavan, R. Armstrong, D. Normile, D. Zhang, and K. Tunceli. "Results from a U.S. Dog Owner Survey on the Treatment Satisfaction and Preference for Fluralaner against Flea and Tick Infestations." *J Vet Sci Technol* 2017 8:3
- [41] H. Dongus "Bravecto® – neue orale Floh- und Zeckenbekämpfung beim Hund mit bis zu zwölf Wochen Wirksamkeit  
Kleintiermedizin Aus der industrie

- [42] H.S. Kokubun, A.L.M. Costa, V.L. Ribeiro, R.P. Gomes, M.H. Paschoalotti, and R.H.F. Teixeira. "Efficient treatment of flea infestation with oral fluralaner in eight captive maned wolves (*Chrysocyon brachyurus*). 2016 Joint AAZV/EAZWV/IZW Conference Proceedings
- [43] G. Sheinberg, C. Romero, R. Heredia, M. Capulin, E. Yarto, and J. Carpio. "Use of oral fluralaner for the treatment of *Psoroptes cuniculi* in 15 naturally infested rabbits." *Vet Dermatol* 2017
- [44] H.S. Han, C. Noli, and T. Cena. "Efficacy and duration of action of oral fluralaner and spot-on moxidectin/imidacloprid in cats infested with *Lynxacarus radovskyi*." *Vet Dermatol* 2016; 27: 474
- [45] C. Romero, G. Sheinberg Waisburd, J. Pineda, R. Heredia, E. Yarto, and A.M. Cordero. "Fluralaner as a single dose oral treatment for *Caparinia tripilis* in a pygmy African hedgehog." *Vet Dermatol* 2017
- [46] A. Loza, A. Talaga, G. Herbas, R.J. Canaviri, T. Cahuasiri, L. Luck, A. Guibarra, R. Goncalves, J.A. Pereira, S.A. Gomez, A. Picado, L.A. Messenger, C. Bern, and O. Courtenay. "Systemic insecticide treatment of the canine reservoir of *Trypanosoma cruzi* induces high levels of lethality in *Triatoma infestans*, a principal vector of Chagas disease." *Parasites & Vectors* 2017 10:344
- [47] G. Machicote-Goth. "Canine straelensiosis. Efficacy of an isoxazoline in the treatment of 7 clinical cases." *Clínica Veterinaria de Pequeños Animales* 2017 37(1 )
- [48] J.L. González, Y. Moral, and M Sánchez. "Eficacia terapéutica de fluralaner en la demodicosis generalizada del perro." *Consulta Difus Vet* 2015
- [49] M. Beccati. "Demodicosi canina: promettenti novità in campo terapeutico." *La Settimana Veterinaria* 2016 970 20 luglio
- [50] J. Karas-Tecza, and J. Dawidowicz. "Efficacy of fluralaner for the treatment of canine demodicosis" *Veterinary Dermatology* 2015 26:297-313
- [51] S.N. Koch. "Updates on the management of canine demodicosis ." *typjournal.com* 2017 jan/feb
- [52] C.M. Zewe, L. Altet, A.T. H. Lam, and L. Ferrer. "Afoxolaner and fluralaner treatment do not impact on cutaneous Demodex populations of healthy dogs." *Vet Dermatol* 2017
- [53] F.M. Walther, P. Fisara, M.J. Allan, and K.A. Roepke. "Sicurezza del trattamento concomitante con fluralaner spot-on e deltametrina per applicazione topica nel cane." *Veterinaria* 2017 31(4)
- [54] H. Dongus. "Bravecto® für die Katze: innovative Zecken- und Flohbekämpfung mit 12 Wochen Wirksamkeit." *Kleintiermedizin* 2016 1 Juli/August 196 – 198.
- [55] P. Fisara, M. Shipstone, A. von Berky, and J. von Berky. "A small-scale open-label study of the treatment of canine flea allergy dermatitis with fluralaner." *Vet Dermatol* 2015
- [56] I. Matricoti, E. Maina "The use of oral fluralaner for the treatment of feline generalized demodicosis: a case report." *Journal of Small Animal Practice* 2017 58: 476-479
- [57] European public MRL assessment report (EPMAR) fluralaner (poultry). EMA/CVMP/567262/2016.